QSAR study of a series of acyl coenzyme A (CoA): cholesterol acyltransferase inhibitors using genetic function approximation

被引:7
作者
Chhabria, Mahesh T. [1 ]
Mahajan, Bhushan M. [1 ]
Brahmkshatriya, Pathik S. [1 ]
机构
[1] Gujarat Univ, LM Coll Pharm, Dept Pharmaceut Chem, Ahmadabad 380009, Gujarat, India
关键词
Acyl CoA cholesterol acyl transferase; Coronary heart disease; Hyperlipidemia; Atherosclerosis; Cross-validation; Quantitative structure activity relationship; Genetic function approximation; PARTICLE SWARM OPTIMIZATION; EXPRESSION; ATHEROSCLEROSIS; REGRESSION;
D O I
10.1007/s00044-010-9413-3
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In cells, cholesterol esters are synthesized in an intracellular reaction catalyzed by acyl coenzyme A (CoA): cholesterol acyltransferase (ACAT) enzymes and, hence, inhibition of ACAT remains as a vital strategy for treatment of hyperlipidemia. Fobare et al. has reported potent ACAT inhibitory activity in a series of N,N',NaEuro(3)-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-diones. QSAR models for these series were developed using genetic function approximation (GFA). Molecular solubility, Jurs, and Shadow descriptors were found to influence biological activity significantly. Lipophilicity of compounds was found to have a critical role in ACAT inhibition along with other structural, spatial, and electronic descriptors. Positive contribution of molecular shadow descriptors suggests that molecules with bulkier substituents are more likely to improve the potency. Developed models were found to be predictive as evidenced from their internal and external cross-validation statistics.
引用
收藏
页码:1573 / 1580
页数:8
相关论文
共 22 条
[1]  
ARIANNA G, 2008, J MED CHEM, V51, P1474
[2]   QSAR of adenosine A3 receptor antagonist 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives using chemometric tools [J].
Bhattacharya, P ;
Roy, K .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (16) :3737-3743
[3]   Recent developments in the treatment of atherosclerosis [J].
Brahmkshatriya, PS ;
Jani, MH ;
Chhabria, MT .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2006, 21 (01) :1-15
[4]   Mammalian acyl-CoA: cholesterol acyltransferases [J].
Buhman, KF ;
Accad, M ;
Farese, RV .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1529 (1-3) :142-154
[5]   Acyl-coenzyme A: Cholesterol acyltransferase [J].
Chang, TY ;
Chang, CCY ;
Cheng, D .
ANNUAL REVIEW OF BIOCHEMISTRY, 1997, 66 :613-638
[6]   Update on patented cholesterol absorption inhibitors [J].
Chhabria, M. T. ;
Mahajan, B. M. .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (08) :1083-1107
[7]  
Cho DH, 2001, B KOR CHEM SOC, V22, P388
[8]  
FOBARE WF, 1993, Patent No. 5179216
[9]   Carbonic anhydrase inhibitors: the first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides [J].
Jaiswal, M ;
Khadikar, PV ;
Scozzafava, A ;
Supuran, CT .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (12) :3283-3290
[10]   Three-dimensional quantitative structure-activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials [J].
Karki, RG ;
Kulkarni, VM .
BIOORGANIC & MEDICINAL CHEMISTRY, 2001, 9 (12) :3153-3160